Quetiapine tablets for immediate release
DOI:
https://doi.org/10.35954/SM2019.38.2.5Keywords:
tablets, schizophrenia, quetiapine fumarate, bipolar disorder, depressive disorderAbstract
Quetiapine is a drug widely used in various psychiatric treatments, such as schizophrenia, bipolar disorder, and dementia. The present work presents different formulations for the manufacture of tablets of quetiapina fumarate of immediate liberation, by means of the methods of direct compression as also by granulation by humid route; the physicochemical characteristics of the quetiapina fumarate (being this the salt usually used) as being; its solubility dependent on the pH and the properties of the powder that make it easily segregated, do of this drug a challenge at the time of achieving good formulations. The aim is to obtain robust formulations that comply with good pharmacological properties at the time of manufacture, as well as to obtain tablets with a good release of the drug.
Received for review: April 2019
Accepted for publication: September 2019
Correspondence: Av. 8 de Octubre 3020. Zip Code 11600. Montevideo, Uruguay. Tel.: (+598) 24876666 ext. 1669.
Contact email: mnoelmf@gmail.com
Downloads
References
Devlin JW, Roberts RJ, Fong JJ, Skrobik Y, Riker RR, Hill NS, et al. Efficacy and safety of quetiapine in critically ill patients with delirium: A prospective, multicenter, randomized, double-blind, placebo-controlled pilot study. Crit Care Med 2010; 38(2):419-27. https://doi.org/10.1097/CCM.0b013e3181b9e302
Allemann SS, Bornand D, Hug B, Hersberger KE, Arnet I. Issues around the Prescription of Half Tablets in Northern Switzerland: The Irrational Case of Quetiapine. BioMed Res Int (en línea) 2015: 5-6, 8 páginas. https://doi.org/10.1155/2015/602021. Available from: https://www.researchgate.net/publication/280314617_Issues_around_the_Prescription_of_Half_Tablets_in_Northern_Switzerland_The_Irrational_Case_of_Quetiapine [Consulta 20/08/2019].
Brett J. Concerns about quetiapine. Aust Prescr 2015; 38:95-97. https://doi.org/10.18773/austprescr.2015.032
Coe HV, Hong IS. Safety of Low Doses of Quetiapine When Used for Insomnia. Ann Pharmacother 2012; 46(5):718-22. https://doi.org/10.1345/aph.1Q697
Huang X, Zhang S, Ma Y, Yang H, He C, Tian R, et al. Bioequivalence of two quetiapine extended release tablets in Chinese healthy volunteers under fasting and fed conditions and effects of food on pharmacokinetic profiles. Drug Des Devel Ther 2019:13 255-264. https://doi.org/10.2147/DDDT.S182965
Gjestad C, Haslemo T, Andreassen OA, Molden E. 4β-Hydroxycholesterol level significantly correlates with steady-state serum concentration of the CYP3A4 substratequetiapine in psychiatric patients. Br J Clin Pharmacol 2017; 83(11):2398-2405. https://doi.org/10.1111/bcp.13341
Akhlaq M, Maryam F, Elaissari A, Ullah H, Adeel M, Hussain A, et al. Pharmacokinetic evaluation of quetiapinefumarate controlled release hybrid hydrogel: a healthier treatment of schizophrenia. Drug Deliv 2018; 25(1):916-927. https://doi.org/10.1080/10717544.2018.1458922
Krishnaraj K, Chandrasekar MJN, Nanjan MJ, Muralidharan S, Manikandan D. Development of sustained release antipsychotic tablets using novel polysaccharide isolated from Delonixregia seeds and its pharmacokineticstudies. Saudi Pharm J 2012; 20(3):239-48. https://doi.org/10.1016/j.jsps.2011.12.003
Khan ZA, Tripathi R, Mishra B. Design and evaluation of enteric coated microporous osmotic pump tablet (Ecmopt) of quetiapinefumarate for the treatment of psychosis. Acta Pol Pharm 2012; 69(6):1125-1136.
Garbacz G, Kandzi A, Koziolek M, Mazgalski J, Weitschies W. Release Characteristics of Quetiapine Fumarate Extended Release Tablets Under Biorelevant Stress Test Conditions. AAPS Pharm Sci Tech 2014; 15(1):230-6. https://doi.org/10.1208/s12249-013-0050-2
Korinde Annemarie J, Beuningen NL, inventors. Synthon BV, assignee. Pharmaceutical composition of quetiapinefumarate. US patent 7.959,948 B2. 2011 Jun14.
Aljaberi1 A, Ardakani A, Khdair1 A, Abdel-Rahim SA, Meqdadi E, Ayyash M, et al. Tableting functionality evaluation of Prosolv Easy tabin comparison to physical mixtures of its individual components. J Drug Del Sci Tech 2013; 23(5):499-504.
Sodium stearyl fumarate. En: Rome RC, Sheskey PJ, Quinn ME.Handbook of Pharmaceutical Excipients. Sixth ed. Somerset: Pharmaceutical Press, 2009. p. 667-669.
Sodium lauryl sulfate. En: Rome RC, Sheskey PJ, Quinn ME. Handbook of Pharmaceutical Excipients. Sixth ed. Somerset: Pharmaceutical Press, 2009. p. 651-653.
Talc. En: Rome RC, Sheskey PJ, Quinn ME. Handbook of Pharmaceutical Excipients. Sixth ed. Somerset: Pharmaceutical Press, 2009. p. 728-730.
Cellulose microcrystalline. En: Rome RC, Sheskey PJ, Quinn ME. Handbook of Pharmaceutical Excipients. Sixth ed. Somerset: Pharmaceutical Press, 2009. p. 129-133.
Lactose spray dried. En: Rome RC, Sheskey PJ, Quinn ME. Handbook of Pharmaceutical Excipients. Sixth ed. Somerset: Pharmaceutical Press, 2009. p. 376-378.
Arida AI, Al-Tabakha MM, Dababneh BF, Al-Jawad FH, Khanfar MS. Identification of the Consolidation Mechanisms of Emcompress ®. J J P S 2008; 1(2):111-125.
EMCOMPRESS ® Calcium Hydrogen Phosphate, Ph.Eur., E 341(ii) Dibasic Calcium Phosphate, USP/NF, FCC.JRS Pharma JRS Family. Available from: https://www.jrspharma.com/pharmawAssets/docs/brochures/emcompress-gb-1911.pdf [Consulta 14/05/2019].
Sodium starch glycolate. En: Rome RC, Sheskey PJ, Quinn ME. Handbook of Pharmaceutical Excipients. Sixth ed. Somerset: Pharmaceutical Press, 2009. p. 663-666.
Magnesium stearate. En: Rome RC, Sheskey PJ, Quinn ME. Handbook of Pharmaceutical Excipients. Sixth ed. Somerset: Pharmaceutical Press, 2009. p. 404-406.
Colloidal silicon dioxide. En: Rome RC, Sheskey PJ, Quinn ME. Handbook of Pharmaceutical Excipients. Sixth ed. Somerset: Pharmaceutical Press, 2009. p. 185-188.
Povidone. En: Rome RC, Sheskey PJ, Quinn ME. Handbook of Pharmaceutical Excipients. Sixth ed. Somerset: Pharmaceutical Press, 2009. p. 581-585.
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 María Noel Martínez Franco. The author retains his copyright and assigns to the journal the right of first publication of his work, which will be simultaneously subject to the Creative Commons Attribution 4.0 International License that allows sharing the work as long as the initial publication in this journal is indicated.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Until 2024 we use the Creative Commons Attribution/NonCommercial Attribution 4.0 International License https://creativecommons.org/licenses/by-nc/4.0/deed.es. Which states that: you are free to share, copy and redistribute the material in any medium or format, as well as to adapt, remix, transform and build upon the material. Under the following terms:
Attribution: you must give proper credit , provide a link to the license, and indicate if changes have been made . You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
NonCommercial: you may not use the material for commercial purposes.
As of 2025 authors retain their copyright and assign to the journal the right of first publication of their work, which shall simultaneously be subject to the license https://creativecommons.org/licenses/by-nc-sa/4.0/deed.es that permits sharing, copying and redistribution of the material in any medium or format provided that initial publication in this journal is indicated. Adapt, remix, transform and build upon the material. If you remix, transform, or build from the material, you must distribute your contribution under the same license as the original and may not make use of the material for commercial purposes.
Under the following terms:
1. Attribution: you must give proper credit, provide a link to the license, and indicate whether changes have been made. You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
2. NonCommercial: you may not use the material for commercial purposes.
3. ShareAlike: if you remix, transform or build upon the material, you must distribute your contribution under the same license as the original.
PlumX Metrics
